Información de Supernus Pharmaceuticals Inc, dividendo de Supernus Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Supernus Pharmaceuticals Inc Compañía

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Información de Supernus Pharmaceuticals Inc



Símbolo de cotizaciónSUPN

Nombre de la empresaSupernus Pharmaceuticals Inc

Fecha de salida a bolsaDec 28, 2010

Director ejecutivoMr. Jack A. Khattar

Número de empleados674

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 28

Dirección9715 Key West Avenue

CiudadROCKVILLE

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal20850

Teléfono13018382500

Sitio Webhttps://www.supernus.com

Símbolo de cotizaciónSUPN

Fecha de salida a bolsaDec 28, 2010

Director ejecutivoMr. Jack A. Khattar

Ejecutivos de Supernus Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

10.67K

+10.74%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

901.00

-92.89%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Ms. Bethany L. Sensenig

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

Otro

15.60M

9.43%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

165.45M

100.00%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

Otro

15.60M

9.43%

Estadísticas de accionistas

Actualizado: vie., 15 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

Otro

57.03%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

Otro

57.03%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

52.68%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

17.15%

Individual Investor

4.28%

Research Firm

2.30%

Pension Fund

1.59%

Venture Capital

1.47%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.10%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

575

60.19M

104.97%

-3.36M

2025Q2

565

63.61M

113.46%

-2.51M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

2023Q3

534

60.88M

111.42%

-4.46M

2023Q2

534

61.11M

111.93%

-1.60M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

8.01M

14.29%

-191.39K

-2.33%

Jun 30, 2025

The Vanguard Group, Inc.

6.19M

11.04%

+41.36K

+0.67%

Jun 30, 2025

Armistice Capital LLC

4.81M

8.58%

-384.00K

-7.39%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.02M

5.39%

+117.48K

+4.05%

Jun 30, 2025

Macquarie Investment Management

2.76M

4.93%

+62.46K

+2.31%

Jun 30, 2025

Khattar (Jack A)

2.15M

3.84%

+54.63K

+2.60%

Sep 30, 2025

State Street Investment Management (US)

2.21M

3.94%

+63.21K

+2.95%

Jun 30, 2025

Renaissance Technologies LLC

1.66M

2.95%

+69.60K

+4.39%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.40M

2.5%

+72.99K

+5.50%

Jun 30, 2025

Stephens Investment Management Group, LLC

1.58M

2.82%

-157.39K

-9.05%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

AdvisorShares Psychedelics ETF

5.4%

iShares Neuroscience and Healthcare ETF

4.31%

Invesco Pharmaceuticals ETF

2.88%

SPDR S&P Pharmaceuticals ETF

2.49%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.89%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.86%

Invesco S&P SmallCap Health Care ETF

1.7%

Lattice Hartford Multifactor Small Cap ETF

1.04%

iShares U.S. Pharmaceuticals ETF

0.99%

First Trust Multi-Manager Small Cap Opportunities ETF

0.59%

AdvisorShares Psychedelics ETF

Proporción5.4%

iShares Neuroscience and Healthcare ETF

Proporción4.31%

Invesco Pharmaceuticals ETF

Proporción2.88%

SPDR S&P Pharmaceuticals ETF

Proporción2.49%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.89%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción1.86%

Invesco S&P SmallCap Health Care ETF

Proporción1.7%

Lattice Hartford Multifactor Small Cap ETF

Proporción1.04%

iShares U.S. Pharmaceuticals ETF

Proporción0.99%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción0.59%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos